Overview

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the potential for a PK drug-drug interaction when IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination. Safety and tolerability will also be assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Janssen Research & Development, LLC

Treatments:

Ritonavir
Simeprevir